Elhadi, 465 patient aspirin late treatment study: 10% lower mortality [p=0.5] https://c19p.org/elhadie
copied to clipboard
Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study
et al., PLOS ONE, doi:10.1371/journal.pone.0251085
Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
|
risk of death, 9.7% lower, RR 0.90, p = 0.50, treatment 22 of 40 (55.0%), control 259 of 425 (60.9%), NNT 17.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Elhadi et al., 4/30/2021, prospective, Libya, Africa, peer-reviewed, 21 authors, study period 29 May, 2020 - 30 December, 2020.
Late treatment
is less effective
is less effective
elhadi
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.